IN2012DN01964A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01964A
IN2012DN01964A IN1964DEN2012A IN2012DN01964A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A IN 1964DEN2012 A IN1964DEN2012 A IN 1964DEN2012A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A
Authority
IN
India
Prior art keywords
metformin
amount
disclosed
subject
chemotherapeutic agents
Prior art date
Application number
Other languages
English (en)
Inventor
Kevin Struhl
Heather Hirsch
Dimitrios Iliopoulos
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IN2012DN01964A publication Critical patent/IN2012DN01964A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1964DEN2012 2009-08-25 2010-08-25 IN2012DN01964A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23677809P 2009-08-25 2009-08-25
PCT/US2010/046616 WO2011031474A2 (fr) 2009-08-25 2010-08-25 Utilisation de metformine dans le traitement et la prévention du cancer

Publications (1)

Publication Number Publication Date
IN2012DN01964A true IN2012DN01964A (fr) 2015-08-21

Family

ID=43733025

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1964DEN2012 IN2012DN01964A (fr) 2009-08-25 2010-08-25

Country Status (14)

Country Link
US (1) US20120220664A1 (fr)
EP (1) EP2470170A4 (fr)
JP (1) JP2013503171A (fr)
KR (1) KR20120080579A (fr)
CN (1) CN102596192A (fr)
AU (1) AU2010292599A1 (fr)
BR (1) BR112012004281A2 (fr)
CA (1) CA2772120A1 (fr)
IL (1) IL218287A0 (fr)
IN (1) IN2012DN01964A (fr)
MX (1) MX2012002337A (fr)
SG (1) SG178556A1 (fr)
WO (1) WO2011031474A2 (fr)
ZA (1) ZA201201434B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040310A1 (en) * 2009-12-15 2013-02-14 Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
WO2012075679A1 (fr) * 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Procédés de ciblage métabolique de cellules cancéreuses utilisant la chimiothérapie et l'immunothérapie pour le traitement du cancer
US9532984B2 (en) * 2011-06-10 2017-01-03 The Translational Genomics Research Institute Therapeutic combination for cancer treatment
CN102327256B (zh) * 2011-09-22 2014-01-29 上海交通大学医学院附属瑞金医院 二甲双胍在制备治疗淋巴瘤疾病药物中的应用
WO2013086002A1 (fr) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, procédé de préparation de ladite composition et méthode de traitement du cancer
US9622982B2 (en) * 2013-01-14 2017-04-18 Health Clinics Limited Cancer drug and uses
SG10201913730RA (en) 2013-04-12 2020-03-30 Rebecca Bent Cancer therapy
JP6242071B2 (ja) * 2013-04-23 2017-12-06 国立大学法人 岡山大学 免疫疲弊ｃｄ８＋ｔ細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬
CN105263484B (zh) 2013-05-24 2018-08-03 株式会社加龄.营养研究所 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途
WO2015183794A1 (fr) 2014-05-27 2015-12-03 City Of Hope Complexes d'agonistes de tgr5 pour le traitement du diabète et du cancer
EP3179994B1 (fr) * 2014-08-14 2019-04-24 The Medical College of Wisconsin, Inc. Composés de mito-metformine et leurs procédés de synthèse et d'utilisation
SG11201700978SA (en) * 2014-08-19 2017-03-30 Univ Okayama Nat Univ Corp Method for enhancing immune cell function and method for assessing immune cell multifunctionality
WO2016026933A1 (fr) * 2014-08-21 2016-02-25 Centre National De La Recherche Scientifique - Cnrs - Traitement adjuvant ou néoadjuvant de sensibilisation de cellules souches cancéreuses à une chimiothérapie
WO2017142485A1 (fr) * 2016-02-16 2017-08-24 Agency For Science, Technology And Research Établissement de profil épigénétique de cancer
CA3059210C (fr) * 2016-05-19 2022-07-19 The Regents Of The University Of California Combinaison de trois medicaments (metformine, simvastatine, digoxine) pour le traitement cible du cancer du pancreas
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
CA3060509A1 (fr) 2017-04-21 2018-10-25 Federica Sotgia Ciblage de cellules souches cancereuses hypoxiques (csc) a l'aide de doxycycline : implications pour ameliorer une therapie anti-angiogenique
CA3060510A1 (fr) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamine c et doxycycline : polytherapie letale synthetique pour eradiquer des cellules souches cancereuses (csc)
EP3624840A4 (fr) 2017-05-19 2021-03-10 Lunella Biotech, Inc. Antimitoscines : inhibiteurs ciblés de biogenèse mitochondriale pour éradiquer les cellules souches cancéreuses
WO2019183003A1 (fr) * 2018-03-18 2019-09-26 The University Of North Carolina At Chapel Hill Procédés et dosages pour des maladies de l'endomètre
CN111617255B (zh) * 2019-02-28 2023-08-18 北京强新生物科技有限公司 用于治疗中枢神经系统紊乱的组合疗法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
DE102006026026A1 (de) * 2006-06-01 2007-12-06 Grünenthal GmbH Arzneimittel
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2008110491A2 (fr) * 2007-03-09 2008-09-18 University Of Basel Chimiothérapie de maladies néoplasiques à l'aide de combinaisons de rapamycine et de composés modulant la voie mtor, individuellement ou en combinaison avec la chaleur
WO2009101199A2 (fr) * 2008-02-15 2009-08-20 Bodo Melnik Traitement de l'acné vulgaire, de la rosacée et du rhinophyme

Also Published As

Publication number Publication date
JP2013503171A (ja) 2013-01-31
MX2012002337A (es) 2012-06-25
CN102596192A (zh) 2012-07-18
WO2011031474A2 (fr) 2011-03-17
CA2772120A1 (fr) 2011-03-17
US20120220664A1 (en) 2012-08-30
KR20120080579A (ko) 2012-07-17
EP2470170A2 (fr) 2012-07-04
EP2470170A4 (fr) 2013-01-02
SG178556A1 (en) 2012-03-29
AU2010292599A1 (en) 2012-03-15
IL218287A0 (en) 2012-04-30
BR112012004281A2 (pt) 2016-03-08
WO2011031474A3 (fr) 2011-06-16
ZA201201434B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
IN2012DN01964A (fr)
IL258880A (en) Compounds of diarylhydantoin
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
TW200621240A (en) Cancer treatments
MX365138B (es) Inhibidores de prolil hidroxilasa.
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MY158106A (en) Inhibitors of e1 activating enzymes
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
WO2011056021A3 (fr) Utilisation de dérivés de benzohétérocycle pour prévenir ou traiter un cancer ou pour inhiber la métastase cancéreuse
MX363579B (es) Composiciones farmaceuticas y metodos.
MX2013010770A (es) Tratamiento de tumores solidos.
MY169330A (en) Method for inhibition of deubiquitinating activity
SG163595A1 (en) Use of tocotrienol composition for the prevention of cancer
WO2009105217A3 (fr) Inhibiteurs du complément en tant qu&#39;agents thérapeutiques pour le traitement du cancer
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2006060819A3 (fr) Dhmeq utilise en tant qu&#39;agent sensibilisateur a des fins de chimiotherapie et d&#39;immunotherapie des cellules cancereuses resistantes
SG191174A1 (en) Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
WO2009158526A3 (fr) Procédés de réduction de prolifération cellulaire par l’inhibition d’acsvl3
EP1547596A4 (fr) Composition medicamenteuse et methode de traitement des tumeurs malignes et d&#39;utilisation de ladite composition medicamenteuse
EA200970418A1 (ru) Применение мультитаргетного ингибитора киназ для лечения или предупреждения рака головного мозга
NZ604127A (en) Neuroendocrine tumor treatment using mtor inhibitors
WO2006085033A3 (fr) Compositions pharmaceutiques destinees au traitement du cancer de la prostate
MXNL05000001A (es) Conjugados de carbohidrato-somatostina-14.
UA101610C2 (ru) Наночастица, которая содержит рапамицин и альбумин, в качестве противоракового агента